HIGHLIGHTS
- who: Pison Christophe from the (UNIVERSITY) have published the paper: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes, in the Journal: (JOURNAL)
- what: The AIRFLOW-1 study assessed safety and TLD dose in patients with moderate-to-severe symptomatic This analysis evaluated the long-term impact of TLD on exacerbations pulmonary function and quality of life over 3 years of follow up. This study has limitations, principally the small cohort size, and a lack of a sham-control group. This study provided long-term followup data on TLD . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.